<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675672</url>
  </required_header>
  <id_info>
    <org_study_id>NRT_MISO Study</org_study_id>
    <nct_id>NCT03675672</nct_id>
  </id_info>
  <brief_title>Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer</brief_title>
  <official_title>Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with a history of idiopathic gastroduodenal ulcer bleeding face an increased risk of&#xD;
      recurrent ulcer gastrointestinal bleeding. Our ongoing clinical trial demonstrates a possible&#xD;
      reduced risk of recurrent idiopathic gastroduodenal ulcer bleeding with proton pump inhibitor&#xD;
      (PPI), yet there is a significant risk of recurrent ulcer bleeding as PPI may increase the&#xD;
      risk of small bowel bleeding. Our preliminary data provide strong plausibility that a&#xD;
      combination therapy of misoprostol (MISO) with a PPI reduces the recurrent ulcer bleeding as&#xD;
      well as clinical gastrointestinal bleeding. The investigators are going to provide the&#xD;
      definitive answer to this important clinical question through a randomised trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS The hypothesis that a combination therapy of misoprostol and lansoprazole is&#xD;
      superior to lansoprazole alone for the prevention of recurrent ulcer bleeding in patients&#xD;
      with a history of idiopathic ulcer bleeding.&#xD;
&#xD;
      STUDY DESIGN OVERVIEW It is a two-year, double blinded, randomized trial of a combination&#xD;
      therapy with misoprostol with PPI (lansoprazole) versus misoprostol placebo plus PPI&#xD;
      (lansoprazole) in patients with a history of idiopathic ulcer bleeding.&#xD;
&#xD;
      Randomization All eligible patients will be randomly assigned (in a 1:1 ratio) to receive 24&#xD;
      months of either misoprostol 800 micrograms daily (i.e. misoprostol 200 micrograms four times&#xD;
      daily) combined with lansoprazole 30 mg once daily, or misoprostol placebo four times daily&#xD;
      plus lansoprazole 30 mg once daily. A computer-generated randomisation schedule is used to&#xD;
      assign patients to the treatment sequences. Concealment of allocation will be ascertained by&#xD;
      an independent research staff member. The Clinical Research Pharmacy located in Prince of&#xD;
      Wales Hospital will dispense consecutively numbered, identical packs that contain sealed&#xD;
      bottles of the study medications.&#xD;
&#xD;
      Follow-up assessment After the randomisation visit, patients will return at month 2, month 6,&#xD;
      and then every four months thereafter until 24 months (follow up Â± 14 days from scheduled&#xD;
      clinic visit is allowed). At each visit, patients' complete blood picture, renal and liver&#xD;
      function tests, and serum salicylate level, compliance to study medications, and the use of&#xD;
      other medications including over-the-counter drugs, and safety of the treatment will be&#xD;
      assessed. Drug adherence is assessed by counting the study drugs. Patients are permitted to&#xD;
      take antacids to relieve dyspepsia. Drugs prohibited during the study include anticoagulant&#xD;
      agents, NSAIDs, cyclooxygenase-2 inhibitors, over-the-counter analgesics (including herbal&#xD;
      products), corticosteroids, misoprostol, sucralfate, antiplatelet drugs, bisphosphonates, and&#xD;
      PPIs/H2RAs apart from the study drugs.&#xD;
&#xD;
      :&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent ulcer bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrent ulcer bleeding confirmed endoscopically. Clinical gastrointestinal bleeding is as defined as haematemesis, per-rectal bleeding and/or melena confirmed and documented by the attending doctor, or a drop in haemoglobin level of 2 g/dL from baseline or more. An ulcer is defined as a circumscribed mucosal break at least 5 mm in the largest diameter and with an observable depth. Bleeding erosion is defined as a break in gastric or duodenal mucosa of any size with the co-existence of blood in the upper gastrointestinal tract.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent gastrointestinal bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrent gastrointestinal bleeding (both upper and lower gastrointestinal bleeding) as defined according to the clinical criteria stated in primary endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Active Peptic Ulcer Disease/GI Bleeding</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol Oral tablet, 200mcg, QID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet, 1 tab, QID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol Oral Tablet</intervention_name>
    <description>Misoprostol 200mcg</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Misoprostol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Tablet</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Idiopathic gastroduodenal ulcer bleeding is defined as described in our previous&#xD;
             studies [12-15]:&#xD;
&#xD;
             Gastroduodenal ulcer bleeding is diagnosed based on:&#xD;
&#xD;
             i. History of symptoms of upper gastrointestinal bleeding with endoscopically proven&#xD;
             gastroduodenal ulcers;&#xD;
&#xD;
             Idiopathic ulcer is diagnosed based on:&#xD;
&#xD;
             i. No experience of ulcerogenic agents (e.g. aspirin, NSAIDs), or drugs of an unknown&#xD;
             nature including traditional Chinese medicine during the 4 weeks before&#xD;
             hospitalization of gastrointestinal bleeding episode; ii. Negative biopsy urease test&#xD;
             and absence of H. pylori on histology in the absence of acid suppressive agents; and&#xD;
             iii. No other cause of ulceration identified (e.g. hypergastrinaemia, Crohn's disease,&#xD;
             cytomegalovirus and herpes infection).&#xD;
&#xD;
          2. Resume hemoglobin level which is same as or higher than the level prior to last ulcer&#xD;
             bleeding episode or stable hemoglobin level (drop &lt;2g/dL) within one year prior&#xD;
             randomization iii.3. No reported gastroduodenal ulcer or ulcer bleeding from last&#xD;
             upper endoscopy 2.4. Aged 18 years old or above. 3.5. Written informed consent&#xD;
             obtained. Fingerprint of subject with a witness involved in the consent procedure will&#xD;
             be accepted for illiterate subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study if they have any of the followings:&#xD;
&#xD;
          1. Concomitant steroid or anticoagulant&#xD;
&#xD;
          2. Concomitant use of NSAIDs, aspirin or COX2 inhibitors&#xD;
&#xD;
          3. Previous gastric surgery&#xD;
&#xD;
          4. Requirement of maintenance PPI (e.g. reflux esophagitis)&#xD;
&#xD;
          5. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4&#xD;
             or above) or active malignancy&#xD;
&#xD;
          6. Subjects who are or will be pregnant or lactating&#xD;
&#xD;
          7. Subjects who have known hypersensitivity or allergies to any component of misoprostol&#xD;
             and lansoprazole.&#xD;
&#xD;
          8. Subject who has current or historical evidence of hypergastrinaemia syndrome or other&#xD;
             hypersecretory condition.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace LH Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace LH Wong, MD</last_name>
    <phone>3505 3476</phone>
    <email>wonglaihung@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica YL Ching, MSc</last_name>
    <phone>3505 3524</phone>
    <email>jessicaching@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Center, Prince of Wales Hospital, Shatin</name>
      <address>
        <city>Hongkong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace LH Wong, MD</last_name>
      <email>wonglaihung@cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Jessica YL Ching, MSc</last_name>
      <email>jessicaching@cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Prof Wong, Lai Hung Grace</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

